The biotech’s G12D-selective RAS blocker has demonstrated its first and second-line combinatory potential in pancreatic ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...

Targeted compound daraxonrasib successfully blocks multiple KRAS variants to double survival limits in clinical trials.

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

At a pivotal moment for pancreatic cancer, Break Through Cancer and the Lustgarten Foundation today, with support from the ...

A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how the drug works.

Dr. Kyaw Zin Thein was in the middle of a difficult conversation. His patient — a man in his 70s — was running out of options ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

Raj Aji has been visiting San Diego regularly since last summer, and not for the weather. The retired Bay Area attorney flies ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than ...